Protagonist Therapeutics, Inc. $PTGX Shares Bought by TD Asset Management Inc

TD Asset Management Inc grew its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 5.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 158,730 shares of the company’s stock after purchasing an additional 8,302 shares during the period. TD Asset Management Inc owned about 0.25% of Protagonist Therapeutics worth $13,863,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. Farallon Capital Management LLC boosted its position in Protagonist Therapeutics by 0.4% in the 3rd quarter. Farallon Capital Management LLC now owns 6,196,006 shares of the company’s stock worth $411,601,000 after purchasing an additional 24,000 shares in the last quarter. Vanguard Group Inc. boosted its position in Protagonist Therapeutics by 27.2% in the 4th quarter. Vanguard Group Inc. now owns 5,413,690 shares of the company’s stock worth $472,832,000 after purchasing an additional 1,156,461 shares in the last quarter. State Street Corp boosted its position in Protagonist Therapeutics by 18.5% in the 2nd quarter. State Street Corp now owns 3,207,543 shares of the company’s stock worth $177,281,000 after purchasing an additional 500,924 shares in the last quarter. UBS Group AG boosted its position in Protagonist Therapeutics by 46.1% in the 4th quarter. UBS Group AG now owns 2,770,021 shares of the company’s stock worth $241,934,000 after purchasing an additional 874,013 shares in the last quarter. Finally, Wellington Management Group LLP boosted its position in Protagonist Therapeutics by 83.9% in the 3rd quarter. Wellington Management Group LLP now owns 1,908,446 shares of the company’s stock worth $126,778,000 after purchasing an additional 870,708 shares in the last quarter. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Insider Buying and Selling

In other Protagonist Therapeutics news, Director Harold E. Selick sold 24,000 shares of the firm’s stock in a transaction on Thursday, March 26th. The stock was sold at an average price of $105.00, for a total value of $2,520,000.00. Following the completion of the sale, the director directly owned 60,845 shares of the company’s stock, valued at $6,388,725. This trade represents a 28.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Arturo Md Molina sold 15,000 shares of the firm’s stock in a transaction on Thursday, March 26th. The stock was sold at an average price of $104.79, for a total value of $1,571,850.00. Following the completion of the sale, the insider directly owned 84,115 shares of the company’s stock, valued at $8,814,410.85. This trade represents a 15.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 263,345 shares of company stock worth $26,707,266 in the last ninety days. Company insiders own 5.19% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Truist Financial upped their price objective on Protagonist Therapeutics from $110.00 to $121.00 and gave the stock a “buy” rating in a research report on Tuesday, April 14th. Wolfe Research assumed coverage on Protagonist Therapeutics in a research report on Thursday, May 21st. They issued an “outperform” rating and a $135.00 price objective on the stock. Citizens Jmp upped their price objective on Protagonist Therapeutics from $120.00 to $137.00 and gave the stock a “market outperform” rating in a research report on Wednesday, May 6th. TD Cowen upped their price objective on Protagonist Therapeutics from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Finally, Citigroup restated an “outperform” rating on shares of Protagonist Therapeutics in a research report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $115.21.

Protagonist Therapeutics Stock Performance

Shares of PTGX stock opened at $98.03 on Tuesday. The stock’s fifty day moving average is $101.25 and its two-hundred day moving average is $92.64. The firm has a market capitalization of $6.30 billion, a P/E ratio of -54.16 and a beta of 1.86. Protagonist Therapeutics, Inc. has a fifty-two week low of $49.38 and a fifty-two week high of $107.84.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.55. The company had revenue of $56.37 million for the quarter, compared to analyst estimates of $11.70 million. Protagonist Therapeutics had a negative return on equity of 17.76% and a negative net margin of 154.88%. On average, equities analysts forecast that Protagonist Therapeutics, Inc. will post 2.93 earnings per share for the current year.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.